Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBN-2397 plus Keytruda for advanced squamous non-small cell lung cancer
MOH_2022-07-04_010803Phase 2Not yet recruiting
- Sponsor
- Ribon Therapeutics
- Start
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atamparib and pembrolizumab in Pulmonary squamous cell carcinoma, sponsored by Ribon Therapeutics. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
atamparibpembrolizumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on MOH_2022-07-04_010803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-04_010803.